SONOMA PHARMACEUTICALS, INC. (SNOA) Return on equity 2017–2026
SONOMA PHARMACEUTICALS, INC. (SNOA) return on equity by fiscal year — reported net income divided by year-end shareholders’ equity.
-102.6%FY2026 · since FY2017: 43.3% → -102.6%
| Fiscal year | Value | YoY |
|---|---|---|
| FY2026 | -102.6% | -24.2 pp |
| FY2025 | -78.4% | +0.4 pp |
| FY2024 | -78.8% | -14.2 pp |
| FY2023 | -64.6% | -6.1 pp |
| FY2022 | -58.5% | +15.2 pp |
| FY2021 | -73.7% | -14.8 pp |
| FY2020 | -58.8% | +93.0 pp |
| FY2019 | -151.8% | -58.4 pp |
| FY2018 | -93.5% | -136.8 pp |
| FY2017 | 43.3% | — |
ROE = reported net income ÷ reported year-end shareholders’ equity for the same fiscal year. Heavy buybacks shrink equity and can push ROE very high (or negative-equity years drop out).
Source: SEC XBRL filings · For reference only · Not investment advice
More SNOA financial trends
SNOA RevenueSNOA Net incomeSNOA Net marginSNOA Gross profitSNOA Gross marginSNOA Operating incomeSNOA Operating marginSNOA Operating cash flowSNOA Free cash flowSNOA Capital expendituresSNOA Stock buybacksSNOA Dividends paidSNOA Total assetsSNOA Total liabilitiesSNOA Shareholders’ equitySNOA overview →